Agios Pharmaceuticals Form 4: New RSU & Option Grants to Director
Rhea-AI Filing Summary
Form 4 Overview – Agios Pharmaceuticals, Inc. (AGIO)
Director Catherine Owen reported three equity transactions dated 18-20 June 2025.
- New equity grants (18-Jun-25): • 2,816 Restricted Stock Units (RSUs) that vest 100 % on 18-Jun-26. • 15,768 stock options with a $35.50 exercise price, also vesting fully on 18-Jun-26 and expiring 18-Jun-35.
- RSU conversion (20-Jun-25): 2,120 previously granted RSUs were settled into an equivalent number of common shares (Code M) at a cost basis of $0.
- Post-transaction ownership: Owen now holds 6,073 common shares directly, plus 2,816 RSUs and 15,768 vested-to-come options.
The activity represents routine director compensation and does not involve open-market buying or selling. No cash proceeds to the insider were disclosed, and the option strike price sits near recent trading ranges, indicating market-aligned pricing. The grants marginally increase Agios’ potential share count but are immaterial relative to the company’s outstanding shares.
Positive
- Aligned incentives: One-year cliff vesting on RSUs and options promotes retention and long-term orientation without immediate sell pressure.
Negative
- Minor dilution: Up to 20,700 additional shares (<0.05 % of float) may be issued upon vesting and exercise, marginally diluting existing shareholders.
Insights
TL;DR: Standard equity grants; governance-friendly, minimal dilution.
The Form 4 records a typical annual equity package for an outside director. Full-vesting after one year aligns incentives while avoiding staggered quarterly vesting that can complicate board independence perceptions. The single-tranche 15,768-share option block at $35.50 reflects fair-market value, satisfying NYSE compensation guidelines. Combined with 2,816 RSUs, the award is modest versus Agios’ ~55 million shares outstanding, implying <0.04 % potential dilution—well within normal governance tolerances. The conversion of 2,120 previously vested RSUs simply transfers book entries; no cash changes hands. Overall, neutral to shareholders and supportive of long-term alignment.
TL;DR: Insider not buying or selling; neutral signal for AGIO.
Investors often track Form 4s for buy/sell cues. Here, Owen receives stock rather than purchasing it, so conviction can’t be inferred. Option strike parity with spot price neither telegraphs bullishness nor undervaluation insight. The incremental dilution—about 20,700 shares including RSUs—has a sub-0.05 % EPS impact, immaterial to valuation models. Accordingly, I view the filing as not impactful for AGIO’s near-term trading outlook.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted stock units | 2,120 | $0.00 | -- |
| Exercise | Common stock | 2,120 | $0.00 | -- |
| Grant/Award | Restricted stock units | 2,816 | $0.00 | -- |
| Grant/Award | Stock options (right to buy) | 15,768 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
FAQ
What did AGIO Director Catherine Owen report in the latest Form 4?
At what price were the new AGIO stock options granted?
When will Catherine Owen’s new RSUs vest?
Does the filing indicate insider buying or selling of AGIO stock?
